The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES(2022)

引用 6|浏览7
暂无评分
摘要
Venetoclax, a B-cell lymphoma (BCL-2) inhibitor, in combination with hypomethylating agents has become the new standard of care in elderly and unfit patients with acute myeloid leukemia, with significantly improved overall survival and quality of life. Studies of venetoclax combined with high-dose chemotherapy are emerging with evidence of higher rates of molecular remission. Recently, a growing number of publications bring forth the use of venetoclax in patients with acute lymphoblastic leukemia (ALL). In the current review, we present the biological rationale of BCL-2 inhibition in ALL, how the interplay of BH3 proteins modulate the response and the current clinical experience with various combinations.
更多
查看译文
关键词
venetoclax,acute lymphocytic leukemia,BCL-2
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要